At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
Researchers are assessing JCAR017 in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The people in this study have CLL or SLL that came back or keeps growing after treatment.
-
Researchers are assessing neladalkib for people with non-small cell lung cancer (NSCLC). The people in this study have NSCLC that has spread beyond its original location. In addition, their cancers have a fusion (genetic change) involving a gene called ALK.
-
Researchers want to know if eating a plant-based diet and taking certain nutritional supplements may be helpful for reducing the risk of progression to multiple myeloma in people with monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM). People with MGUS and SMM have an abnormal protein called the M protein in their blood and are at risk of developing multiple myeloma.
-
The purpose of this study is to assess stereotactic radiosurgery (SRS) to treat people with small cell lung cancer (SCLC) who have been newly diagnosed with brain metastases (cancer that spread to the brain). SRS specifically targets a very small area of the body. By targeting the part of the brain where the cancer has spread, SRS may shrink the cancer without damaging healthy brain tissue.
- A Phase 2 Study of Axatilimab Plus Ruxolitinib in Adults and Children With Chronic Graft-Versus-Host Disease
Full Title A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
Purpose
With chronic graft-versus-host disease (cGVHD), healthy stem cells from a donor see the recipient’s healthy cells as foreign and attack. This commonly happens about 100 days after a stem cell transplant, but it can happen at any time.
Researchers want to see if a steroid-free approach using ruxolitinib, with or without axatilimab, works well to treat cGVHD. Ruxolitinib blocks JAK proteins, which may reduce inflammation (swelling) and immune system reactions related to GVHD. Axatilimab blocks a protein called CSF-1R that controls white blood cells which play a role in GVHD.
If you join this study, you will be randomly assigned to get one of these treatments:
- Axatilimab and ruxolitinib. Axatilimab is given intravenously (by vein) and ruxolitinib is taken orally (by mouth).
- Ruxolitinib alone.
- Corticosteroids alone (methylprednisolone or prednisone, taken orally).
Who Can Join
To join this study, there are a few conditions. You or your child must:
- Have moderate to severe cGVHD that has not yet been treated.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 12 or older.
Contact
For more information or to see if you or your child can join this study, please call Dr. Doris Ponce’s office at 646-608-3739.
Protocol
24-318Phase
Phase II (phase 2)Disease Status
Newly DiagnosedInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06388564ClinicalTrials.gov
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
Inotuzumab ozogamicin is a drug used to treat adults with B-cell acute lymphoblastic leukemia (ALL) that has come back or continued to grow despite prior therapy. In this study, researchers are evaluating its use in children and young adults with recurrent or persistent B-cell ALL.
-
Researchers want to see if combining pembrolizumab, ibrutinib, and rituximab works well against primary central nervous system lymphoma (PCNSL). The people in this study have PCNSL that keeps growing or came back even with treatment.
- A Phase 2 Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia
Full Title A Phase 2 Study of Azacitidine and Venetoclax to Treat Acute Myeloid Leukemia Patients with Measurable Residual Disease before an Allogeneic Stem Cell Transplant
Purpose
Some people treated for acute myeloid leukemia (AML) with induction (initial) chemotherapy are left with minimal residual disease (MRD). With MRD, there is a small number of leukemia cells from the bone marrow remaining in the body. MRD increases the chance that the cancer will come back after a bone marrow transplant from a donor.
The drugs azacitidine and venetoclax may work well to get rid of or lower MRD in people with AML. Researchers are doing this study to see if this can be achieved with one treatment cycle of azacitidine and venetoclax. They hope that giving these drugs before a bone marrow transplant will reduce the chance of the leukemia coming back. Azacitidine is given intravenously (by vein) or as an injection, and venetoclax is taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have AML with MRD after induction chemotherapy.
- Be planning to receive a bone marrow transplant from a donor.
- Be age 18 or older.
- You may join this study even if you need help taking care of yourself. You may also join even if you are in a bed or chair for more than half the time you’re awake.
Contact
For more information or to see if you can join this study, please call Dr. Eytan Stein’s office at 646-608-3749.
Protocol
24-347Phase
Phase II (phase 2)Investigator
Co-Investigators
Locations
ClinicalTrials.gov ID
NCT06773208ClinicalTrials.gov
-
The genetic and biochemical makeup of a tumor influences its aggressiveness and the choice of the most appropriate therapy. The purpose of this research study is to determine the genetic and biochemical makeup of neuroblastic tumors, including neuroblastoma, ganglioneuroblastoma, ganglioneuroma, and paraganglioma. These research studies will include analysis of substances called markers that exist on the surface of cancer cells; cytogenetic studies; the identification of genes related to the development of these cancers and to tumor growth; and studies of tumor growth in test tubes. Patients' blood and bone marrow will also be tested for the presence of tumor cells or leukemia cells.